Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Circulating tumour cells as biomarkers

AACR 2009

18 - 22 Apr 2009

Published: 5 Jun 2009

Views: 17645

Rating:

Save

Dr Howard Scher - Sloan Kettering Memorial Cancer Center

Dr Howard I. Scher, Chief, Genitourinary Oncology Service; D. Wayne Calloway Chair in Urologic Oncology, Sloan Kettering Memorial Cancer Center, US, talking to ecancer at AACR 2009 about Circulating tumour cells as biomarkers. Prostate cancer staging. Abiraterone acetate.

Related Videos

Choosing the right patients for transplant

Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Choosing the right patients for transplant ( Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India )

Choosing Wisely in endometrial & cervix cancers: Medical therapy

Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India

Choosing Wisely in endometrial & cervix cancers: Medical therapy ( Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes

Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes ( Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK )

More from ecancer